Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Messages That Motivate: Communicating Alcohol-Related Breast Cancer Risk to Young Adult Women (MEMO)

2 de septiembre de 2026 actualizado por: Darren Mays, Ohio State University Comprehensive Cancer Center
This is an online cross-sectional experimental survey study examining two cancer communication questions: 1) What features of social media messages communicating the breast cancer risks from alcohol consumption will motivate young adult women to drink less? and 2) Do message features differ in their persuasive effects based on young adult women's alcohol consumption behavior?

Descripción general del estudio

Descripción detallada

This is an online cross-sectional experimental study to examine the effects of features of social media messages in young adult women ages 18-25 who drink alcohol based on valid, self-report outcomes. Within the survey, participants will be randomized to view messages in one of nine conditions in a 3x3 factorial design with baseline alcohol consumption as a within-participants factor to test the effects of social media message features (content, persuasive themes) on participant responses. We will also compare the effects of message features for young women who drink within recommended limits (1 drink/day or less on average) and those who exceed recommended drinking limits.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

900

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: The Ohio State University Comprehensive Cancer Center
  • Número de teléfono: 800-293-5066
  • Correo electrónico: OSUCCCClinicaltrials@osumc.edu

Ubicaciones de estudio

    • Ohio
      • Columbus, Ohio, Estados Unidos, 43210
        • The Ohio State University Comprehensive Cancer Center
        • Investigador principal:
          • Darren Mays, MPH, PhD
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto

Acepta Voluntarios Saludables

Sí

Descripción

Inclusion Criteria:

  • Assigned female at birth
  • Age 18-25
  • Report drinking alcohol at least once in the past 30 days
  • Registered in the United States as a member of the Prolific consumer research platform
  • Willing and able to complete procedures in English

Exclusion Criteria:

  • Assigned male at birth
  • Ages <18 or >25
  • Do not report drinking alcohol at least once in the past 30 days
  • Not registered in the U.S. as a member of the Prolific consumer research platform
  • Not willing or not able to complete procedures

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Arm 1: Risk Only + Industry Deception
Risk message content
Messages with information about alcohol industry deception
Experimental: Arm 2: Risk Only + YAW Susceptibility
Risk message content
Message content with information about why young adult women are susceptible to breast cancer risk from alcohol consumption
Experimental: Arm 3: Risk Only + Mechanisms
Risk message content
Message content with information about the mechanism by which alcohol contributes to increased breast cancer risk
Experimental: Arm 4: Efficacy Only + Industry Deception
Messages with information about alcohol industry deception
Efficacy Message Content
Experimental: Arm 5: Efficacy Only + YAW Susceptibility
Message content with information about why young adult women are susceptible to breast cancer risk from alcohol consumption
Efficacy Message Content
Experimental: Arm 6: Efficacy Only + Mechanisms
Message content with information about the mechanism by which alcohol contributes to increased breast cancer risk
Efficacy Message Content
Experimental: Arm 7: Risk and Efficacy + Industry Deception
Risk message content
Messages with information about alcohol industry deception
Efficacy Message Content
Experimental: Arm 8: Risk and Efficacy + YAW Susceptibility
Risk message content
Message content with information about why young adult women are susceptible to breast cancer risk from alcohol consumption
Efficacy Message Content
Experimental: Arm 9: Risk and Efficacy + Mechanisms
Risk message content
Message content with information about the mechanism by which alcohol contributes to increased breast cancer risk
Efficacy Message Content

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Message Perceptions
Periodo de tiempo: This assessment is administered immediately after participants view study messages on Day 1

We will assess message perceptions using a valid, reliable measure with six questions about whether participants thought the messages were worth remembering, grabbed their attention, and were informative, powerful, convincing, and meaningful. Responses are on a five-point Likert scale from 1 (Strongly disagree) to 5 (Strongly agree).

For all message response outcomes, we will sum and average responses to the items to create message-level scores, then compute means across both messages within each condition for a grand mean. Higher values are considered a better outcome.

This assessment is administered immediately after participants view study messages on Day 1
Effect Perceptions
Periodo de tiempo: This assessment is administered immediately after participants view study messages on Day 1
We will capture message effects perceptions using the abbreviated effects perceptions scale. Items include questions about how much the messages made them feel discouraged to drink alcohol, concerned about drinking alcohol, and made them feel that drinking alcohol is unpleasant on a scale from 1 (Strongly disagree) to 5 (Strongly agree). For all message response outcomes, we will sum and average responses to the items to create message-level scores, then compute means across both messages within each condition for a grand mean. Higher values are considered a better outcome.
This assessment is administered immediately after participants view study messages on Day 1
Emotional Response
Periodo de tiempo: This assessment is administered immediately after participants view study messages on Day 1
We will capture emotional responses to the messages using a valid, four item scale. Items are "This message made me angry; irritated; aggravated; and annoyed" with responses on a 5-point Likert scale from 1 (Not likely at all) to 5 (Extremely likely). For all message response outcomes, we will sum and average responses to the items to create message-level scores, then compute means across both messages within each condition for a grand mean. Higher values are considered a better outcome.
This assessment is administered immediately after participants view study messages on Day 1
Counter-arguing
Periodo de tiempo: This assessment is administered immediately after participants view study messages on Day 1
We will capture counter-arguing, a measure of whether participants cognitively refute messages, with a valid, three item scale that captures whether participants criticize messages, think of points that go against messages, and are skeptical of the messages. Responses are on a 5-point Likert scale ranging from 1 (Not at all) to 7 (Very much). For all message response outcomes, we will sum and average responses to the items to create message-level scores, then compute means across both messages within each condition for a grand mean. Lower values are considered a better outcome.
This assessment is administered immediately after participants view study messages on Day 1
Behavioral Intentions
Periodo de tiempo: This assessment is administered immediately after participants view study messages on Day 1
Intentions to reduce alcohol consumption in the future will also be assessed with a valid, multi-item scale capturing whether participants will avoid drinking alcohol completely, reduce the number of occasions when they drink alcohol, and reduce the amount of alcohol they consume on drinking occasions with a 1 (Definitely Will Not) to 4 (Definitely Will) response scale. For all message response outcomes, we will sum and average responses to the items to create message-level scores, then compute means across both messages within each condition for a grand mean. Higher values are considered a better outcome.
This assessment is administered immediately after participants view study messages on Day 1

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Darren Mays, MPH, PhD, The Ohio State University Comprehensive Cancer Center

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de octubre de 2026

Finalización primaria (Estimado)

30 de junio de 2028

Finalización del estudio (Estimado)

1 de julio de 2028

Fechas de registro del estudio

Enviado por primera vez

28 de agosto de 2026

Primero enviado que cumplió con los criterios de control de calidad

2 de septiembre de 2026

Publicado por primera vez (Actual)

3 de septiembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

3 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • OSU-26048
  • R01CA311193-01 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

De-identified individual participant data from self-report measures will be deposited in the Inter-university Consortium for Political and Social Research (ICPSR). ICPSR will make the research data from this project available to the broader social science research community as public-use data files. These files, in which direct and indirect identifiers have been removed to minimize disclosure risk, may be accessed directly through the ICPSR website.

Marco de tiempo para compartir IPD

The research data from this project will be supplied to ICPSR at the time of publication of the relevant results or at the end of the project period, whichever is sooner, so that any issues surrounding the usability of the data can be resolved. Delayed dissemination may be possible. The Delayed Dissemination Policy allows for data to be deposited but not disseminated for an agreed-upon period (typically one year).

Criterios de acceso compartido de IPD

After agreeing to Terms of Use, users with an ICPSR MyData account and an authorized IP address from a member institution may download the data, and non-members may purchase the files.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir